Free shipping on orders from 160 €from 160 € 3-vial Retatrutide 30 mg pack at 150 € See the packs
ORDER

Cagrilintide: side effects and safety

Clinical trials provide a fairly accurate picture of the tolerability of cagrilintide, alone or in combination with semaglutide. This data pertains to a drug in development, manufactured and controlled by Novo Nordisk. Here are the figures, and what they don't reveal.

Our Janoshik analysis

Key takeaways

  • The most frequent side effects are digestive: nausea, constipation and vomiting.
  • They are more frequent with CagriSema than with cagrilintide alone.
  • In the trials, they were most often mild to moderate and decreased over time.
  • These figures come from controlled trials. They say nothing about a product used outside of this framework.

Cagrilintide alone

In the phase 2 trial (Lau et al., 2021), 706 adults received cagrilintide, liraglutide, or a placebo for 26 weeks. Depending on the dose, gastrointestinal disturbances affected 41% to 63% of participants receiving cagrilintide, compared to 32% in the placebo group. Nausea ranged from 20% to 47%, compared to 18% in the placebo group. Overall, 4% of participants discontinued the trial due to an adverse event.

In the phase 3 REDEFINE 1 trial, 1.0% of participants in the cagrilintide-only group discontinued treatment due to nausea, compared to 0.1% in the placebo group.

With semaglutide (CagriSema)

Adverse effect (REDEFINE 1, 68 weeks)CagriSemaPlacebo
Digestive problems79,6 %39,9 %
Nausea55 %12,6 %
Constipation30,7 %11,6 %
Vomiting26,1 %4,1 %
Discontinuation due to adverse event5,9 %3,5 %

Nausea, constipation, vomiting and discontinuations: figures from Novo Nordisk press release dated December 18, 2025.

In people with type 2 diabetes (REDEFINE 2), digestive disorders affected 72.5% of participants in the CagriSema group, compared to 34.4% in the placebo group, and 8.4% discontinued treatment due to an adverse event, compared to 3.0%. In REDEFINE 5, conducted in East Asia, their frequency was close to that of semaglutide alone: 53% versus 51%.

These side effects are linked to the molecule's mechanism of action: by slowing gastric emptying, cagrilintide prolongs the feeling of fullness, but can also cause nausea. Other effects have been measured: in REDEFINE 1, systolic blood pressure decreased by 10.9 mmHg with CagriSema, compared to 2.8 mmHg with placebo (Verma et al., 2026). Rarer events are detailed in the full trial reports.

Official alerts

Cagrilintide is not authorized in any country: outside of clinical trials, its manufacture and purity are not controlled by any health authority. In the United States, the FDA reiterates that it cannot be used in compounded medications. In France, the ANSM (National Agency for Medicines and Health Products Safety) issued a warning on July 2, 2026, regarding peptides sold online, with instructions not to use them and citing hospitalizations. This warning does not mention cagrilintide. In September 2025, the ANSM and the European Medicines Agency had already issued a warning about the increase in illegal or counterfeit weight-loss drugs sold online.

Cagrilintide and anti-doping

Cagrilintide is not specifically mentioned in the World Anti-Doping Agency's 2026 list. However, it falls under class S0, which permanently prohibits any substance without authorization for therapeutic use, including molecules undergoing clinical development.

How reliable are online reviews?

Numerous testimonials can be found on forums and social media. These testimonials do not allow for any conclusions: they are unverified, the actual composition of the products is unknown, and the described effects may have other causes. A certificate of analysis indicates the contents of a vial. It says nothing about tolerability, and our Janoshik report does not address sterility or endotoxins.

Frequently asked questions

What are the side effects of cagrilintide?

Mostly digestive disorders. In the phase 2 trial, they affected 41% to 63% of participants on cagrilintide alone depending on the dose, compared to 32% on placebo, with nausea in 20% to 47% of cases.

Does CagriSema cause more side effects?

Yes. In REDEFINE 1, 79.6% of participants taking CagriSema experienced digestive problems, compared to 39.9% in the placebo group. Nausea affected 55% of them.

Does cagrilintide cause constipation?

In REDEFINE 1, constipation affected 30.7% of participants on CagriSema, compared to 11.6% on placebo, according to Novo Nordisk.

Is cagrilintide banned in sports?

Yes. Lacking marketing authorization, it falls under the World Anti-Doping Agency's S0 class, which is permanently prohibited.

What to do in case of an adverse effect?

Consult a healthcare professional and report the effect on signalement-sante.gouv.fr.

Sources: Lau D.C.W. et al., Lancet 2021; Garvey W.T. et al., N Engl J Med 2025 (REDEFINE 1); Davies M.J. et al., N Engl J Med 2025 (REDEFINE 2); Yamauchi T. et al., 2026 (REDEFINE 5); Verma S. et al., Hypertension 2026; Novo Nordisk, press release of 18/12/2025; ANSM, alerts of 09/09/2025 and 02/07/2026; EMA, 03/09/2025; FDA, 01/10/2026; World Anti-Doping Agency, 2026 list. MyPeptide products are intended exclusively for scientific laboratory research.

FRENDEITESPTNLPLSV
Back to top